Poly(lactide-co-glycolide) microspheres: A potent oral delivery system to elicit systemic immune response against inactivated rabies virus

Vaccine

Volumn 27, Issue 15, 2009, Pages 2138-2143

  Ramya, R ^a   Verma, P C ^a   Chaturvedi, V K ^a   Gupta, P K ^a   Pandey, K D ^a   Madhanmohan, M ^b   Kannaki, T R ^a   Sridevi, R ^a   Anukumar, B ^a  

^a INDIAN VETERINARY RESEARCH INSTITUTE   (India)

^b Indian Immunologicals Limited   (India)

Author keywords

Oral immunization; Poly(lactide co glycolide (PLG); Rabies

Indexed keywords

CONCANAVALIN A; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INACTIVATED VIRUS VACCINE; MICROSPHERE; NEUTRALIZING ANTIBODY; POLYGLACTIN; PROPIOLACTONE; RABIES VACCINE; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; EXPERIMENTAL MOUSE; HUMORAL IMMUNITY; IMMUNE RESPONSE; LETHAL DOSE; LYMPHOCYTE PROLIFERATION; MICROENCAPSULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; RABIES; RABIES VIRUS; SERODIAGNOSIS; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; VACCINATION; VIRUS INACTIVATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, VIRAL; CRICETINAE; IMMUNOGLOBULIN G; INJECTIONS, INTRAPERITONEAL; MICE; MICROSPHERES; NEUTRALIZATION TESTS; POLYGLACTIN 910; PROPIOLACTONE; RABIES; RABIES VACCINES; RANDOM ALLOCATION; VACCINES, INACTIVATED;

EID: 61549122035     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.129     Document Type: Article

References (34)

1. WHO Expert Consultation on Rabies. World Health Organization. Technical Report Series 2005;931:1-88.
2. LeBlois H., Tuffereau C., Blancou J., Artois M., Aubert A., and Flamand A. Oral immunization of foxes with avirulent rabies virus mutants. Vet Microbiol 23 (1990) 259-266
3. Brochier B., Kieny M.P., Costy F., Coppens P., Bauduin B., Lecocq J.P., et al. Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature 354 (1991) 520-522
4. Schneider L.G. Rabies virus vaccines. Dev Biol Stand 84 (1995) 49-54
5. Rupprecht C.E., Dietzschold B., Campbell J.B., Charlton K.M., and Koprowski H. Consideration of inactivated rabies vaccines as oral immunogens of wild carnivores. J Wildlife Dis 28 (1992) 629-635
6. Morris W., Steinhoff M.C., and Russell P.K. Potential of polymer microencapsulation technology for vaccine innovation. Vaccine 12 (1994) 5-11
7. Wise D.L., Fellman T.D., Sanderson J.E., and Wentworth R.L. Lactic/glycolic acid polymers. In: Gregoriadis G. (Ed). Drug carriers in biology and medicine (1979), Academic Press, London 237-270
8. Eldridge J.H., Meulbroek J.A., Staas J.K., Tice T.R., and Gilley R.M. Vaccine-containing biodegradable microspheres specifically enters the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response. Adv Exp Med Biol 25 (1989) 191-202
9. Eldridge J.H., Staas J.K., Meulbroek J.A., Mcghee J.R., Tice T.R., and Gilley R.M. Biodegradable microspheres as a vaccine delivery system. Mol Immunol 28 (1991) 287-294
10. Moldoveanu Z., Stass J.K., Gilley R.M., Ray R., Compans R.W., Eldridge J.H., et al. Immune responses to influenza virus in orally and systematically immunized mice. Curr Top Microbiol Immunol 146 (1989) 91-99
11. O'Hagan D.T., Singh M., Ugozzoli M., Wild C., Barnett S., Chen M., et al. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. J Virol 75 (2001) 9037-9043
12. Jaganathan K.S., and Vyas S.P. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine 24 (2006) 4201-4211
13. Consales C.A., Valentini J.G., Albas A., Mendonca R.M., Fuches R.M., Soares M.A., et al. The preparation of cultured rabies virus and the production of antiserum for human use. J Biol Stand 16 (1988) 27-32
14. Singh H. b-Propiolactone-inactivated sheep brain vaccine. In: Meslin F.X., Kaplan M.M., and Koprowski H. (Eds). Laboratory techniques in rabies. 4th ed. (1996), WHO, Geneva 234-242
15. Cox J.H., Dietzschold B., and Schneider L.G. Rabies virus glycoprotein. II. Biological and serological characterization. Infect Immun 16 (1977) 754-759
16. Wiktor T.J., Dietzschold B., Leamnson R.N., and Koprowski H. Induction and biological properties of defective interfering particles of rabies virus. J Virol 21 (1977) 626-635
17. Rosas J.E., Hernandez A.R., Gascon, Igartua M., Guzman F., Patarroyo M.E., et al. Biodegradable PLG A microspheres as a delivery system for malaria synthetic peptide SPf 66. Vaccine 19 (2001) 4445-4451
18. Lavelle E.C., Yeh M.K., Coombes A.G., and Davies S.S. The stability and immunogenicity of a protein antigen encapsulated in biodegradable microparticle based on blends of lactide polymers and polyethylene glycol. Vaccine 17 (1999) 512-529
19. Fitzgerald E.A. Potency test for antirabies serum and immunoglobulin. In: Meslin F.X., Kaplan M.M., and Koprowski H. (Eds). Laboratory techniques in rabies. 4th ed. (1996), WHO, Geneva 417-422
20. Mosmann T. Rapid colorimetric assay for cellular growth and survival application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
21. Estrada R., Vos A., De Leon R., and Mueller T. Field trail with oral vaccination of dogs against rabies in the Philippines. BMC Infect Dis 1 (2001) 23
22. Jayakumar R., Kumanan K., Nachimuthu K., and Padmanaban V.D. A bait delivery system suitable for oral rabies vaccine for stray dogs in India. Indian Vet J 75 (1998) 207-210
23. Baer G.M., Abelseth M.K., and Debbie J.G. Oral vaccination of foxes against rabies. Am J Epidemiol 93 (1971) 487-490
24. O'Hagan D.T., Rafferty D., Wharton S., and Illum L. Intravaginal immunization in sheep using a bioadhesive microsphere antigen delivery system. Vaccine 11 (1993) 660-664
25. O'Hagan D.T. Prospects for the development of new and improved vaccines through the use of microencapsulation technology. In: Levine M.M., Woodrow G.C., Kaper J.B., and Cobon G.S. (Eds). New generation vaccines (1997), Marcel Dekker, New York 215-228
26. Miller A., Morse III H.C., Winkelstein J., and Nathanson N. The role of antibody in recovery from experimental rabies. I. Effect of depletion of B and T cells. J Immunol 121 (1978) 321-326
27. Smith J.S. Mouse model for abortive rabies infection of the central nervous system. Infect Immun 31 (1981) 297-308
28. Mifune K., Takeuchi E., Napiorkowski P.A., Yamada A., and Sakamoto K. Essential role of T cells in the post-exposure prophylaxis of rabies in mice. Microbiol Immunol 25 (1981) 895-904
29. Dietzschold B., Wang H.H., Rupprecht C.E., Celis E., Tollis M., Ertl H., et al. Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein. Proc Natl Acad Sci USA 84 (1987) 9165-9169
30. Leibowitz S., and Hughes R.A.C. Immunology of the nervous system (1983), Edward Arnold, London
31. Vordermeier H.M., Coombes A.G.A., Jenkins P., McGee J.P., O' Hagan D.T., Davis S.S., et al. Synthetic delivery systems for tuberculosis vaccines: Immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable microparticles. Vaccine 13 (1995) 1576-1582
32. Moore A., McGuirk P., Adams S., Jones W.C., McGee J.P., O'Hagan D.T., et al. Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8 + cytotoxic T lymphocytes and CD4 + TH1 cells. Vaccine 13 (1995) 1741-1749
33. Kovacsovics-Bankowski M., and Rock K. A phagosome to cytosol pathway for exogenous antigens presented on MHC class I molecules. Nature 267 (1995) 243-245
34. Dietzschold B., Tollis M., Lafon M., Wunner W.H., and Koprowski H. Mechanisms of rabies virus neutralization by glycoprotein-specific monoclonal antibodies. Virology 161 (1987) 29-36